Teratogenic determinants of first- trimester exposure to antiepileptic medications

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 18, Issue 1, 2011, Pages

  Brosh, Koby ^a   Matok, Ilan ^f   Sheine, Eyal ^a,c,d   Koren, Gideon ^f,g   Wiznitzer, Arnon ^a,c,d,e   Gorodischer, Rafael ^a,d,e   Levy, Amalia ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Departments of Epidemiology and Health Services Evaluation   (Israel)

^c Departments of Obstetrics and Gynecology   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e CLALIT HEALTH SERVICES   (Israel)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiepileptic medications; Birth defects; Folic acid antagonists; Monotherapy; Phenobarbital; Polytherapy; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FEVER; FIRST TRIMESTER PREGNANCY; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; INFANT; INFORMATION PROCESSING; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SMOKING; MEDICAL RECORD; MONOTHERAPY; PARITY; PERINATAL MORTALITY; PERINATAL PERIOD; PREGNANCY TERMINATION; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SMOKING; TERATOGENICITY; VERY LOW BIRTH WEIGHT;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES;

EID: 79959841337     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005;4:781-786.
2. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009;50:2130-9.
3. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005;46:117-124.
4. Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. Best practice guidelines for the management of women with epilepsy. Seizure 1999;9:201-217.
5. Entink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, de Jong-van den Berg LT; EUROCAT Antiepileptic Study Working Group. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-93.
6. Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen CL; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): I-III. Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1229-55.
7. Kimford J, Meador MD, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; For the NEAD Study Group. Cognitive function after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360:1597-605.
8. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2:937.
9. Central Bureau of Statistics, State of Israel. Statistical Abstract of Israel 2008, No. 59. http://www.cbs.gov.il/ts/ (Accessed March 16, 2009).
10. Central Bureau of Statistics, State of Israel: Available at: http/www.cbs.gov.il/reader/newhodaot/searh_text_hodaot.html (Accessed November 25, 2008).
11. Centers for Disease Control and Prevention: Metropolitan Atlanta Congenital Defects Program. Available at: http://www.cdc.gov/ncbddd/bd/macdp.htm (Accessed December 3, 2009).
12. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A Clin. Mol Teratol 2003; 67: 193-201.
13. Katz O, Levy A, Wiznitzer A, Sheiner E. Pregnancy and perinatal outcome in epileptic women: a population based study. J Matern Fetal Neonatal Med 2006;19:21-5.
14. Sheiner E, Shoham-Vardi I, Sheiner EK, Mazor M, Katz M, Carmi R. Maternal factors associated with severity of birth defects. Int J Gynaecol Obstet 1999; 64: 227-32.
15. Sheiner E, Shoham-Vardi I, Weitzman D, Gohar J, Carmi R. Decisions regarding pregnancy termination among Bedouin couples referred to third level ultrasound clinic. Eur J Obstet Gynecol Reprod Biol 1998; 76: 141-6.
16. Stoltenberg C, Magnus P, Lie RT, Daltveit AK, Irgens LM. Birth defects and parental consanguinity in Norway. Am J Epidemiol 1997;145: 439-48.
17. Zlotogora J. Genetic disorders among Palestinian Arabs: effects of consanguinity. Am J Med Genet 1997;68:472-5.
18. Holmes LB, Wyszynski DF, Lieberman E. The Antiepileptic Drug Pregnancy Registry: a 6-year experience. Arch Neurol 2004;61: 673-78.
19. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58.
20. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575-79.
21. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8.
22. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231-36.
23. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC; NEAD Study Group. In utero antiepileptic drug exposure Neurology 2006;67:407-12.
24. Sawhney H, Vasishta K, Suri V, Khunnu B, Goel P, Sawhney IM. Pregnancy with epilepsy -a retrospective analysis. Int J Gynecol Obstet 1996;54:17-22.
25. Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl. J Med 2009; 360:2528-2535.
26. Ben-Joseph R, Levy A, Wiznitzer A, Holcberg G, Mazor M, Sheiner E. Pregnancy outcome of patients following deep venous thrombosis. J Matern Fetal Neonatal Med 2009 Apr;22(4):332-6.
27. Ofir D, Levy A, Wiznitzer A, Mazor M, Sheiner E. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol 2008 Dec;141(2):115-8.
28. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-49.
29. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group. Teratology 1999; 60: 33-6.
30. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet 1968; 2 (7581): 1296.
31. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-38.
32. Matok I, Gorodischer R, Koren G, Landau D, Wiznitzer A, Levy A. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol 2009;68:956-62.
33. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987;21:176-82.